The Study
The role of the FT3/FT4 ratio in predicting remission and relapse in pediatric Graves’ disease
This study looked back at kids who had Graves’ disease and saw that those who got sick again tended to have a certain blood ratio. But it didn’t change anything or control for other reasons they got sick — so we can’t say the ratio made them relapse, just that it was often higher in those who did.
Analysis score
Maximum 58 for a case-control study.
Where the score came from
Doctors give medicine to kids with an overactive thyroid (Graves' disease) to calm it down. Sometimes it works for good, sometimes it comes back. This study looked at blood numbers at the start to see if they could guess who might get sick again.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 558 / 100
Quality score
Researchers compare people who have a condition (cases) with similar people who do not (controls), looking back in time for differences in exposure. Useful but more prone to bias.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this means doctors could use this blood test to spot kids who need longer treatment or closer monitoring, even if they seem better at first.
- 2If the ratio of two thyroid hormones (FT3/FT4) was above 0.54, it predicted relapse with 98% accuracy (only 2% false alarms).
- 3Kids with TRAb levels below 10 IU/L or smaller thyroids were more likely to stay healthy after stopping medicine.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
European Journal of Pediatrics
Year
2026
Authors
Leyla Kara, Ulku Gul Siraz, D. Çiçek, E. Sarıkaya, Ebru Gok, Uğur Berber, M. Kendirci, S. Kurtoğlu, N. Hatipoğlu
Related Content
Claims (5)
In children with Graves' disease, a baseline FT3/FT4 ratio above 0.54 pmol/pmol correctly identifies 75% of those who will relapse after stopping medication and correctly rules out 98% of those who will not relapse.
Children with Graves' disease who have TRAb levels below 10 IU/L when first diagnosed are more likely to achieve sustained remission after treatment with antithyroid drugs.
Children with Graves' disease who have a larger thyroid gland at diagnosis are less likely to achieve long-term remission after taking antithyroid drugs.
In children diagnosed with Graves' disease, the ratio of free triiodothyronine to free thyroxine at the time of diagnosis does not accurately identify which children will achieve long-term remission after treatment with antithyroid drugs.
Some children with Graves' disease who stop antithyroid drugs and appear to be in remission will experience a return of the disease more than one year later, and in some cases, this happens up to two years after stopping treatment.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.